PR Newswire - Jacobio Pharma Announced its KRAS G12C inhibitor r...
BEIJING and SHANGHAI and BOSTON, April 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offic...
Read More